FoxBio, Inc. is a joint partnership between Juvenescence and Antoxerene, a portfolio company of Ichor Therapeutics. The company is focused on developing small molecule senolytics targeting a major survival pathway relied on by senescent cells.

Antoxerene works to identify and develop novel compounds to attack disease related to aging. Juvenescence will support the venture with equity financing and drug development expertise